Canada Launches Six-Month Dosing of Trelstar for Prostate Cancer Patients

Canada Launches Six-Month Dosing of Trelstar for Prostate Cancer Patients
A new six-month dosing option (22.5 mg) dosage of Trelstar (triptorelin pamoate), a drug indicated for the palliative treatment of hormone dependent advanced prostate cancer, is now available in Canada. This smaller dosage allows patients to receive fewer injections but still provides long-term testosterone suppression, according to a 12-month, multicenter, open-label, Phase 3 clinical study,

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *